盖皮龙-ER对患有严重抑郁症患者的性功能的影响
Tierney K Lorenz1,2,3, Mary F Johnson4, Anita H Clayton5
1Center for Brain, Biology and Behavior, University of Nebraska Lincoln, Lincoln, Nebraska.
The Journal of clinical psychiatry
|October 21, 2024
概括
延长释放 (ER) 基皮龙在严重抑郁症 (MDD) 患者中没有引起性功能障碍,表现出与安慰剂和SSRI相比可比或更好的性功能.
科学领域:
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
- 临床试验 临床试验
背景情况:
- 大型抑郁症 (MDD) 影响全球数以百万计的人,治疗通常与性功能障碍有关.
- 阿扎皮龙和盖皮龙一样,是抗抑郁药的一类药物,其副作用的概况可能不同.
研究的目的:
- 评估长期释放 (ER) 盖皮龙对MDD患者性功能的影响.
- 为了比较gepirone-ER对性功能的影响与安慰剂和选择性血清素再吸收抑制剂 (SSRI).
主要方法:
- 分析了来自5项3期随机对照试验的1,767名患者的数据.
- 通过临床面试和经过验证的调查在8至44周内对性功能进行前性评估.
- 盖皮龙-ER与安慰剂和SSRI在MDD治疗中的比较.
主要成果:
- 盖皮龙-ER在性副作用和治疗引起的性功能障碍方面与安慰剂相等.
- 与SSRI相比,盖皮龙-ER表现出明显更好的性功能结果.
- 盖皮龙-ER在保护性功能方面比SSRI的好处在治疗早期很明显,并保持长期.
结论:
- 在接受MDD治疗的患者中,盖皮龙-ER与性功能障碍无关.
- 盖皮龙-ER的性副作用率与安慰剂可比,低于SSRI的性副作用率.
- 与SSRI相比,盖皮龙-ER为MDD患者提供了有利的性功能概况.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
196
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
196
G-protein Coupled Receptors
116.7K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
116.7K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
212
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
212
Antiepileptic Drugs: Potassium Channel Activators
147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
147
Antidepressant Drugs: Overview
370
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
370
Psychosis: Goals of Pharmacotherapy
104
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
104


